Salta al menu principale di navigazione Salta al contenuto principale Salta al piè di pagina del sito
FrancoAngeli Journals

Paper Scientifico

N. 53 (2020)

Le formulazioni long term dei farmaci agonisti nella clinica del disturbo da uso di oppiacei in Italia

DOI
https://doi.org/10.3280/mis53-2020oa9860
Inviata
21 maggio 2020
Pubblicato
21-05-2020

Riferimenti bibliografici

  1. D’Agnone O. (2019). The OAD Clinic, London, UK. Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine. Case Reports in Psychiatry, Article ID 9381346, 4 pages. doi: 10.1155/2019/9381346.
  2. D’Egidio P.F., Lucchini A. (a cura di) (2012). Uno sguardo sui Ser.T.: la parola agli operatori e ai pazienti. Lo studio nazionale DeMoS. Milano: FrancoAngeli.
  3. D’Egidio P.F., Leonardi C. (a cura di) (2012). La responsabilità dei professionisti nei Ser.T. Milano: FrancoAngeli.
  4. Frost M., Bailey G.L., Lintzeris N., Strang J., Dunlop A., Nunes E.V., Jansen J.B., Frey L.C., Weber B., Haber P., Oosman S., Kim S., Tiberg F. (2019). Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder. Addiction.
  5. Goldstein A. Addiction Research Foundation Palo Alto California NIDA Monograpf Series, Research 34. Problems of Drug Dependence 1880 Published in February 1981.
  6. Goldstein A. (1997). La neurobiologia dell’assuefazione all’eroina e del trattamento metadonico. Chicago, aprile.
  7. Kalivas P.W., Volkow N.D. (2005). The Neural Basis of Addiction: A Pathology of Motivation and Choice. Am J Psychiatry, 162: 1403-1413.
  8. Ling W., Nadipelli V.R., Solem C.T., Ronquest N.A., Yeh Y.-C., Learned S.M., Mehra V., Heidbreder C. (2019). Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Doubleblind, Placebo-controlled, Multicenter, Phase 3 Study. J Addict Med, vol. 13, n. 6, November/December.
  9. Lintzeris N., Dunlop A., Masters D. (2019). Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. Sydney Australia: NSW Ministry of Health.
  10. Lofwall M.R., Walsh S.L., Nunes E.V., Bailey G.L., Sigmon S.C., Kampman K.M., Frost M., Tiberg F., Linden M., Sheldon B., Oosman S., Peterson S., Chen M., Kim S. (2018). Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder. JAMA Internal Medicine, May 14.
  11. Lofwall M.R. (2018). Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder A Randomized Clinical Trial. JAMA Internal Medicine.
  12. Lucchini A. (2014). In Atlante delle Dipendenze, a cura di Leopoldo Grosso e Francesca Rascazzo. Edizioni Gruppo Abele, Torino.
  13. Middleton L., Kelly J., Dargan S., Ritchie T. (2019). Improved recovery outcomes with injectable prolonged-release buprenorphine in an opioid agonist therapy clinic in Glasgow. Glasgow.
  14. Neale J., Tompkins C.N.E., Strang J. (2019). Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences. Drug and Alcohol Review.
  15. Neale J., Tompkins C.N.E., Strang J. (2019). Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations. Harm Reduction Journal: 16-25.
  16. Soyka M., Pogarell O. (2019). Nervenarzt, Sep, 90(9): 932-937. doi: 10.1007/s00115-019-0783-6. [New slow-release buprenorphine formulations for optimization of opioid substitution]. [Article in German].
  17. Tagliamonte A., Meloni D. (2004). Le basi biologiche della dipendenza.
  18. Tompkins C.N.E., Neale J., Strang J. (2019). Opioid users’ willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. Journal of Substance Abuse Treatment, 104: 64-71.
  19. Volkow N.D., Koob G.F., Mc Lellan T. (2016). Neurobiologic Advances from the Brain Disease Model of Addiction. N Engl J Med, 374: 363-71. doi: 10.1056/NEJMra1511480.
  20. Vorspan F., Hjelmström P., Simon N., Benyamina A., Dervaux A., Brousse G., Jamain T., Kosim M., Rolland B. (2019). What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Expert Opinion on Drug Delivery, vol. 16, n. 9: 907-914.
  21. Walsh S.L., Comer S.D., Lofwall M.R., Vince B., Cooperman L., Kelsh D., Coe M.A., Jones J.D., Nuzzo P.A., Tiberg F., Sheldon B., Kim S. (2017). Effect of BuprenorphineWeekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder A Randomized Clinical Trial. JAMA Psychiatry, June 22.
  22. www.federserd.it per la raccolta del periodico scientifico “Mission” e del periodico scientifico FeDerSerD Informa, nonché per la sezione legislativa. Indagini FeDerSerD, sui pazienti in cura nei Ser.T. in Italia. www.federserd.it
  23. Relazione annuale al Parlamento sull’uso di sostanze stupefacenti e sulle tossicodipendenze in Italia. www.politicheantidroga.it

Metriche

Caricamento metriche ...